THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS

• US 20090246181A1
• Filed: 03/27/2009
• Published: 10/01/2009
• Est. Priority Date: 03/28/2008
• Status: Abandoned Application

• Current Assignee: JCR Pharmaceuticals Co., Ltd., Miracure, Inc.
• Original Assignee: JCR Pharmaceuticals Co., Ltd., Miracure, Inc.
• Inventors: Takanashi, Masakatsu, KURODA, Masahiko, Yamauchi, Shigeki, Sudo, Katsuko
• Application Number:
  US12/412,598
• Publication Number:
  US 20090246181A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.

Claims

1. A composition for the treatment of atopic dermatitis comprising human mesenchymal stem cells as the active principle.

2. The composition for the treatment of atopic dermatitis according to claim 1, wherein the atopic dermatitis is that which has developed g in a mammal.

3. The composition for the treatment of atopic dermatitis according to claim 2, wherein the mammal is selected from the group consisting human, dog, cat, rabbit, and rodent.

4. The composition for the treatment of atopic dermatitis according to claim 1, wherein the human mesenchymal stem cells are of human-bone marrow origin.

5. The composition for the treatment of atopic dermatitis according to claim 4, wherein the mammal is a human and is not the same as the human from whom the human mesenchymal stem cells originate.

6. The composition for the treatment of atopic dermatitis according to claim 1, wherein the composition is an injection.

7. The composition for the treatment of atopic dermatitis according to claim 6, wherein the composition is an injection for intravenous administration.

8. A method for the treatment of atopic dermatitis in a patient comprising administering to the patient a therapeutically effective amount of human mesenchymal stem cells.

9. The method for the treatment of atopic dermatitis in a patient according to claim 8, wherein the patient is a mammal.

10. The method for the treatment of atopic dermatitis in a patient according to claim 9, wherein the mammal is selected from the group consisting of human, dog, cat, rabbit, and rodent.

11. The method for the treatment of atopic dermatitis in a patient according to claim 8, wherein the human mesenchymal stem cells are of human bone-marrow origin.